Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant plus adjuvant treatment with immunotherapy may have an anti-tumor activity and
reduce the risk of relapse in patients with high risk surgically resectable stage III
cutaneous squamous cell carcinoma.